CA-ARMIS
16.4.2024 13:01:29 CEST | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, is warning that global elections will be the largest attack vector for nation-state actors looking to cause mass disruption in 2024.
Data from Armis’ second annual global cyberwarfare report, The Invisible Front Line: AI-Powered Cyber Threats Illuminate the Dark Side, show organizations and governments worldwide face critical threat levels from sophisticated nation-states and admittedly are severely underprepared to defend against impending cyberwarfare attacks.
“In the biggest global election year in history, democracy is the primary target of nation-state threat actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “Make no mistake - we are in a cyber arms race against our adversaries and society as we know it is at risk. It’s essential that we immediately shift from a reactive to a proactive, defensive stance before it’s too late.”
Thirty-nine percent of IT leaders worldwide believe cyberwarfare could affect the integrity of an electoral process and 42% believe cyberwarfare could target the media. As half of the global population across 76 nations prepare to head to the polls this year, this pre-existing doubt in the sanctity of the electoral process has laid the groundwork for calculated assaults on public trust. When successful, cyberwarfare attacks could destabilize economies and cripple entire commercial and societal systems.
Additionally, 60% of IT leaders say digital transformation projects have stalled or stopped entirely due to cyberwarfare risks. However, innovation has not stalled for bad actors who continue to push the boundaries. Elite researchers from Armis Labs have uncovered the tactics of nation-state actors affiliated with Russia, North Korea, Iran and China that are using AI for advanced cyber capabilities. Armis Labs is also seeing an increase in the combination of weaponized vulnerabilities being used by threat actors in a single attack.
“Relying on legacy technologies and manual security processes is the equivalent of bringing a knife to a gunfight, given the threats we’re up against and the arsenal of nation-state actors,” continued Izrael. “It is critical that security leaders fight fire with fire, leveraging AI-powered solutions that empower them with actionable intelligence before a vulnerability is announced, before an attack is launched and before their organization is impacted. Forewarned is forearmed.”
Armis Centrix™ for Actionable Threat Intelligence is an early warning, AI-based system that leverages dark web, dynamic honeypots and human intelligence (HUMINT) to anticipate threats, understand their potential impact and take preemptive action to neutralize them, effectively moving the security posture from defense to offense.
The 2024 Armis Cyberwarfare Report, The Invisible Front Line: AI-Powered Cyber Threats Illuminate the Dark Side, is based on a study of over 2,600 global IT decision-makers and proprietary data from Armis Labs.
Read the full report from Armis, including a comprehensive breakdown of the findings for each region of respondents, here.
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416828074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
